Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma

NCT07665190 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Hypopharyngeal Squamous Cell Carcinoma

Interventions

DRUG: Becotatug Vedotin and Pucotenlimab

Sponsor

Tianjin Medical University Cancer Institute and Hospital